F. Hoffmann-La Roche Ltd. has divulged pyrimidin-2-yl sulfonamide derivatives acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists reported to be useful for the treatment of obesity, Alzheimer's disease, Parkinson's disease, meningitis, encephalitis, ischemia, demyelinating diseases and schizophrenia.